Fighting fibrin with fibrin: Vancomycin delivery into coagulase-mediated Staphylococcus aureus biofilms via fibrin-based nanoparticle binding.
Staphylococcus aureus
biofilm
dermal infection
fibrin
nanoparticle
vancomycin
Journal
Journal of biomedical materials research. Part A
ISSN: 1552-4965
Titre abrégé: J Biomed Mater Res A
Pays: United States
ID NLM: 101234237
Informations de publication
Date de publication:
14 Jun 2024
14 Jun 2024
Historique:
revised:
02
05
2024
received:
12
02
2024
accepted:
27
05
2024
medline:
14
6
2024
pubmed:
14
6
2024
entrez:
14
6
2024
Statut:
aheadofprint
Résumé
Staphylococcus aureus skin and soft tissue infection is a common ailment placing a large burden upon global healthcare infrastructure. These bacteria are growing increasingly recalcitrant to frontline antimicrobial therapeutics like vancomycin due to the prevalence of variant populations such as methicillin-resistant and vancomycin-resistant strains, and there is currently a dearth of novel antibiotics in production. Additionally, S. aureus has the capacity to hijack the host clotting machinery to generate fibrin-based biofilms that confer protection from host antimicrobial mechanisms and antibiotic-based therapies, enabling immune system evasion and significantly reducing antimicrobial efficacy. Emphasis is being placed on improving the effectiveness of therapeutics that are already commercially available through various means. Fibrin-based nanoparticles (FBNs) were developed and found to interact with S. aureus through the clumping factor A (ClfA) fibrinogen receptor and directly integrate into the biofilm matrix. FBNs loaded with antimicrobials such as vancomycin enabled a targeted and sustained release of antibiotic that increased drug contact time and reduced the therapeutic dose required for eradicating the bacteria, both in vitro and in vivo. Collectively, these findings suggest that FBN-antibiotic delivery may be a novel and potent therapeutic tool for the treatment of S. aureus biofilm infections.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIH HHS
ID : NIH T32GM133393
Pays : United States
Organisme : NIH HHS
ID : 5T34GM131947
Pays : United States
Organisme : NIH HHS
ID : T32GM133366
Pays : United States
Organisme : NIH HHS
ID : NHLBI R01HL162809
Pays : United States
Organisme : NSF
ID : GFRP
Informations de copyright
© 2024 The Author(s). Journal of Biomedical Materials Research Part A published by Wiley Periodicals LLC.
Références
Loomba P, Taneja J, Mishra B. Methicillin and vancomycin resistant S. aureus in hospitalized patients. J Glob Infect Dis. 2010;2(3):275‐283. doi:10.4103/0974‐777X.68535
Kourtis AP, Hatfield K, Baggs J, et al. Vital signs: epidemiology and recent trends in methicillin‐resistant and in methicillin‐susceptible Staphylococcus aureus bloodstream infections—United States. MMWR Morb Mortal Wkly Rep. 2019;68(9):214‐219. doi:10.15585/mmwr.mm6809e1
Ikuta KS, Swetschinski LR, Robles Aguilar G, et al. Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet. 2022;400(10369):2221‐2248. doi:10.1016/S0140‐6736(22)02185‐7
Thomer L, Emolo C, Thammavongsa V, et al. Antibodies against a secreted product of Staphylococcus aureus trigger phagocytic killing. J Exp Med. 2016;213(3):293‐301. doi:10.1084/jem.20150074
Otto M. Staphylococcus aureus toxins. Curr Opin Microbiol. 2014;17:32‐37. doi:10.1016/j.mib.2013.11.004
Ventola CL. The antibiotic resistance crisis: part 1: causes and threats. P T. 2015;40(4):277‐283.
Zapotoczna M, O'Neill E, O'Gara JP. Untangling the diverse and redundant mechanisms of Staphylococcus aureus biofilm formation. PLoS Pathog. 2016;12(7):e1005671. doi:10.1371/journal.ppat.1005671
Foster TJ, Geoghegan JA, Ganesh VK, Höök M. Adhesion, invasion and evasion: the many functions of the surface proteins of Staphylococcus aureus. Nat Rev Microbiol. 2014;12(1):49‐62. doi:10.1038/nrmicro3161
Zapotoczna M, McCarthy H, Rudkin JK, O'Gara JP, O'Neill E. An essential role for coagulase in Staphylococcus aureus biofilm development reveals new therapeutic possibilities for device‐related infections. J Infect Dis. 2015;212(12):1883‐1893. doi:10.1093/infdis/jiv319
Roy S, Santra S, das A, et al. Staphylococcus aureus biofilm infection compromises wound healing by causing deficiencies in granulation tissue collagen. Ann Surg. 2020;271(6):1174‐1185. doi:10.1097/SLA.0000000000003053
Leong HN, Kurup A, Tan MY, Kwa ALH, Liau KH, Wilcox M. Management of complicated skin and soft tissue infections with a special focus on the role of newer antibiotics. Infect Drug Resist. 2018;11:1959‐1974. doi:10.2147/IDR.S172366
Rubinstein E, Keynan Y. Vancomycin revisited—60 years later. Front Public Health. 2014;2:217. doi:10.3389/fpubh.2014.00217
Ceri H, Olson ME, Stremick C, Read RR, Morck D, Buret A. The Calgary biofilm device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol. 1999;37(6):1771‐1776. doi:10.1128/JCM.37.6.1771‐1776.1999
Tuon FF, Suss PH, Telles JP, Dantas LR, Borges NH, Ribeiro VST. Antimicrobial treatment of Staphylococcus aureus biofilms. Antibiotics. 2023;12(1):87. doi:10.3390/antibiotics12010087
Rivani E, Arfijanto MV, Widodo ADW. Vancomycin for methicillin‐resistant Staphylococcus aureus biofilm eradication is associated with the emergence of heterogeneous vancomycin intermediate Staphylococcus aureus. Int J Health Sci. 2022;6(S9):811‐818. doi:10.53730/ijhs.v6nS9.12536
Deresinski S. Vancomycin in combination with other antibiotics for the treatment of serious methicillin‐resistant Staphylococcus aureus infections. Clin Infect Dis. 2009;49(7):1072‐1079. doi:10.1086/605572
Shi J, Mao NF, Wang L, et al. Efficacy of combined vancomycin and fosfomycin against methicillin‐resistant Staphylococcus aureus in biofilms in vivo. PLoS One. 2014;9(12):e113133. doi:10.1371/journal.pone.0113133
Durham PG, Sidders AE, Beam JE, et al. Harnessing ultrasound‐stimulated phase change contrast agents to improve antibiotic efficacy against methicillin‐resistant Staphylococcus aureus biofilms. Biofilm. 2021;3:100049. doi:10.1016/j.bioflm.2021.100049
Guo H, Wang Z, Du Q, Li P, Wang Z, Wang A. Stimulated phase‐shift acoustic nanodroplets enhance vancomycin efficacy against methicillin‐resistant Staphylococcus aureus biofilms. Int J Nanomedicine. 2017;12:4679‐4690. doi:10.2147/IJN.S134525
Ziesmer J, Tajpara P, Hempel NJ, et al. Vancomycin‐loaded microneedle arrays against methicillin‐resistant Staphylococcus aureus skin infections. Adv Mater Technol. 2021;6(7):2001307. doi:10.1002/admt.202001307
Zhao F, Su Y, Wang J, et al. A highly efficacious electrical biofilm treatment system for combating chronic wound bacterial infections. Adv Mater. 2023;35(6):2208069. doi:10.1002/adma.202208069
Scriboni AB, Couto VM, Ribeiro LNM, et al. Fusogenic liposomes increase the antimicrobial activity of vancomycin against Staphylococcus aureus biofilm. Front Pharmacol. 2019;10:1401. doi:10.3389/fphar.2019.01401
Fulaz S, Devlin H, Vitale S, Quinn L, O'Gara JP, Casey E. Tailoring nanoparticle‐biofilm interactions to increase the efficacy of antimicrobial agents against Staphylococcus aureus. Int J Nanomedicine. 2020;15:4779‐4791. doi:10.2147/IJN.S256227
Hassan D, Omolo CA, Fasiku VO, Mocktar C, Govender T. Novel chitosan‐based pH‐responsive lipid‐polymer hybrid nanovesicles (OLA‐LPHVs) for delivery of vancomycin against methicillin‐resistant Staphylococcus aureus infections. Int J Biol Macromol. 2020;147:385‐398. doi:10.1016/j.ijbiomac.2020.01.019
Muhamed I, Sproul EP, Ligler FS, Brown AC. Fibrin nanoparticles coupled with keratinocyte growth factor enhance the dermal wound‐healing rate. ACS Appl Mater Interfaces. 2019;11(4):3771‐3780. doi:10.1021/acsami.8b21056
Roosa CA, Muhamed I, Young AT, et al. Synthesis of sonicated fibrin nanoparticles that modulate fibrin clot polymerization and enhance angiogenic responses. Colloids Surf B Biointerfaces. 2021;204:111805. doi:10.1016/j.colsurfb.2021.111805
Enomoto R, Imamori M, Seon A, et al. Proposal for a new evaluation of phagocytosis using different sizes of fluorescent polystyrene microspheres. Adv Biol Chem. 2013;03(6):556‐563. doi:10.4236/abc.2013.36064
Olivier V, Rivière C, Hindié M, Duval J‐L, Bomila‐Koradjim G, Nagel M‐D. Uptake of polystyrene beads bearing functional groups by macrophages and fibroblasts. Colloids Surf B Biointerfaces. 2004;33(1):23‐31. doi:10.1016/j.colsurfb.2003.08.008
Motyl M, Dorso K, Barrett J, Giacobbe R. Basic microbiological techniques used in antibacterial drug discovery. Curr Protoc Pharmacol. 2005;31(1):13A.3.1‐13A.3.22. doi:10.1002/0471141755.ph13a03s31
Masters EA, de Mesy Bentley KL, Gill AL, et al. Identification of penicillin binding protein 4 (PBP4) as a critical factor for Staphylococcus aureus bone invasion during osteomyelitis in mice. PLoS Pathog. 2020;16(10):e1008988. doi:10.1371/journal.ppat.1008988
Karg M, Pich A, Hellweg T, et al. Nanogels and microgels: from model colloids to applications, recent developments, and future trends. Langmuir. 2019;35(19):6231‐6255. doi:10.1021/acs.langmuir.8b04304
Bjerketorp J. The von Willebrand factor‐binding protein (vWbp) of Staphylococcus aureus is a coagulase. FEMS Microbiol Lett. 2004;234(2):309‐314. doi:10.1016/j.femsle.2004.03.040
Zajdel M, Wegrzynowicz Z, Jeljaszewicz J, Pulverer G. Mechanism of action of staphylocoagulase and clumping factor. Contrib Microbiol Immunol. 1973;1:364‐375.
Fischer K, Litmanovich B, Sivaraj D, et al. Protocol for the splinted, human‐like excisional wound model in mice. Bio Protoc. 2023;13(3):e4606. doi:10.21769/BioProtoc.4606
Dunn L, Prosser HCG, Tan JTM, Vanags LZ, Ng MKC, Bursill CA. Murine model of wound healing. J Vis Exp. 2013;no. 75:e50265. doi:10.3791/50265
Stewart PS. Biophysics of biofilm infection. Pathog Dis. 2014;70(3):212‐218. doi:10.1111/2049‐632X.12118
Song T, Duperthuy M, Wai S. Sub‐optimal treatment of bacterial biofilms. Antibiotics. 2016;5(2):23. doi:10.3390/antibiotics5020023
Andersson DI, Hughes D. Microbiological effects of sublethal levels of antibiotics. Nat Rev Microbiol. 2014;12(7):465‐478. doi:10.1038/nrmicro3270
Siala W, Mingeot‐Leclercq M‐P, Tulkens PM, Hallin M, Denis O, Van Bambeke F. Comparison of the antibiotic activities of daptomycin, vancomycin, and the investigational fluoroquinolone delafloxacin against biofilms from Staphylococcus aureus clinical isolates. Antimicrob Agents Chemother. 2014;58(11):6385‐6397. doi:10.1128/AAC.03482‐14
Jiang Y, Geng M, Bai L. Targeting biofilms therapy: current research strategies and development hurdles. Microorganisms. 2020;8(8):1222. doi:10.3390/microorganisms8081222
Abdullah K, Chen H, Lucas T. Safety of topical vancomycin powder in neurosurgery. Surg Neurol Int. 2016;7(40):S919‐S926. doi:10.4103/2152‐7806.195227
Yrios JW. Comparison of rabbit and pig plasma in the tube coagulase test. J Clin Microbiol. 1977;5(2):221‐224. doi:10.1128/jcm.5.2.221‐224.1977
Alphonsa BM, Sudheesh Kumar PT, Praveen G, Biswas R, Chennazhi KP, Jayakumar R. Antimicrobial drugs encapsulated in fibrin nanoparticles for treating microbial infested wounds. Pharm Res. 2014;31(5):1338‐1351. doi:10.1007/s11095‐013‐1254‐6
Thattaruparambil Raveendran N, Mohandas A, Ramachandran Menon R, Somasekharan Menon A, Biswas R, Jayakumar R. Ciprofloxacin‐ and fluconazole‐containing fibrin‐nanoparticle‐incorporated chitosan bandages for the treatment of polymicrobial wound infections. ACS Appl Bio Mater. 2019;2(1):243‐254. doi:10.1021/acsabm.8b00585
Jordens JZ, Duckworth GJ, Williams RJ. Production of “virulence factors” by “epidemic” methicillin‐resistant Staphylococcus aureus in vitro. J Med Microbiol. 1989;30(4):245‐252. doi:10.1099/00222615‐30‐4‐245